NasdaqGM:HROWPharmaceuticals
Is Harrow's (HROW) Softer 2025 Outlook Exposing a Fragile Revenue Mix Strategy?
In the past few days, Harrow signaled that 2025 revenue could land around US$265 million, falling short of its earlier US$270–US$280 million guidance range, as strength in Iheezo and Vevye is offset by pressure in specialty and compounded segments and one-time factors.
This tension between robust growth in newer ophthalmic products and emerging headwinds in legacy segments raises fresh questions about how balanced Harrow’s revenue mix really is.
Next, we’ll examine how concerns over a...